Immucell Stock Price, News & Analysis

ImmuCell Corporation (Nasdaq: ICCC) will announce its unaudited financial results for the quarter ending March 31, 2022, after market close on May 12, 2022. A conference call is scheduled for May 13, 2022, at 9:00 AM ET to discuss the results. Dr. Joseph H. Crabb will participate to cover the company's science and technology. The Quarterly Report on Form 10-Q will be available post-market close on May 12, 2022, along with a corporate presentation on ImmuCell's business.

ImmuCell Corporation (Nasdaq: ICCC) has appointed Dr. Mark Wustenberg as the new Commercial Leader of Stakeholder Engagement, aimed at launching their innovative product, Re-Tain®, pending FDA approval. Dr. Wustenberg brings significant experience in the dairy industry, having held various leadership roles, including at Tillamook County Creamery. His focus will be on enhancing communication and research efforts to foster product acceptance, benefiting both Re-Tain® and the First Defense® product line. The company is set to discuss its financial results on May 13, 2022.

ImmuCell Corporation (Nasdaq: ICCC) has appointed Dr. Mark Wustenberg as Commercial Leader of Stakeholder Engagement. Dr. Wustenberg brings extensive experience from his previous roles, including Vice President of Sustainability at Tillamook County Creamery. He will focus on the upcoming launch of Re-Tain®, pending FDA approval, and enhancing the market presence of First Defense®. The company aims to improve dairy producer profitability through these initiatives, leveraging Dr. Wustenberg's industry expertise to strengthen its sales and marketing strategy.

ImmuCell Corporation (Nasdaq: ICCC) reported preliminary, unaudited sales of $6.0 million for Q1 2022, a 46% increase from $4.1 million in Q1 2021. This marks a record high for any quarter. The company is expanding its First Defense manufacturing capacity from $16.5 million to $35 million, with annualized output reaching $23.8 million. ImmuCell is also awaiting FDA approval for the Re-Tain product, with a response expected in Q3 2022.

ImmuCell Corporation (Nasdaq: ICCC) reported a strong performance for the year ended December 31, 2021, with product sales increasing by 25% to $19.2 million compared to 2020. In Q4 alone, sales surged by 45% to $5.4 million. The company's gross margin improved to 47% for Q4 and 45% for the year. Net operating income shifted to a gain of $257,000, contrasting with a $1.4 million loss in 2020. Cash and equivalents rose to $10.2 million. A significant FDA submission regarding Re-Tain is expected to impact future market launch plans.

ImmuCell Corporation (Nasdaq: ICCC) plans to announce its unaudited financial results for Q4 and the year ended December 31, 2021, on February 22, 2022. A conference call will be held on February 23, 2022, at 9:00 AM ET, where executives will discuss production capacity investments for the First Defense product line and insights regarding the upcoming launch of Re-Tain.

The Annual Report on Form 10-K is expected to be filed by March 30, 2022. Stakeholders are encouraged to view the updated corporate presentation on the company's website following the financial results announcement.

ImmuCell Corporation (Nasdaq: ICCC) reported preliminary unaudited sales of $19.2 million for 2021, marking a 25% increase from 2020's $15.3 million. The fourth quarter saw sales of $5.4 million, a 45% rise from $3.7 million in the previous year. The company attributes this growth to strategic investments in expanding manufacturing capacity for its First Defense® product, with plans for further investment of $1.8 million to enhance production capabilities to approximately $35 million. ImmuCell is also progressing on its Re-Tain® drug application to the FDA.

ImmuCell Corporation (Nasdaq: ICCC) reported a net income of $148,000 for Q3 2021, a significant turnaround from the net loss of ($323,000) in Q3 2020. Total product sales rose 38% to $5.2 million, while nine-month sales increased 19% to $13.8 million. The company achieved a gross margin of 47% in Q3 2021 and improved EBITDA to approximately $852,000. Cash reserves grew to $10.5 million as of September 30, 2021, up from $7.9 million at year-end 2020. ImmuCell plans to submit another Technical Section to the FDA for its product Re-Tain® by year-end 2021.

ImmuCell Corporation (Nasdaq: ICCC), a company focused on improving the health of dairy and beef cattle, will report unaudited financial results for Q3 and the nine-month period ending September 30, 2021, after market close on November 15, 2021. A conference call will be held on November 16, 2021, at 9:00 AM ET to discuss these results. The Quarterly Report on Form 10-Q will be filed concurrently. Details about their products, including First Defense and Re-Tain, are available on their website.